Dr Grace Lu-Yao speaks to ecancer about fracture risk following cancer therapies for advanced prostate cancer.

The study explores fracture risk in patients undergoing advanced prostate cancer therapy, revealing that risk increases significantly over time, exceeding 20% after five years.

It highlights the limitations of clinical trials, which often exclude older patients and those with comorbidities.

The research shows disparities in fracture risk among racial groups and emphasises the need for patient awareness and better care strategies, as less than half of patients use recommended bone health agents.